- KEI statement: 21st meeting of the WHO Expert Committee on the Selection and Use of Essential Medicines
- Dr. Elias Zerhouni defends Sanofi/Army proposed license on Zika patents, and KEI responds
- Maryland House of Delegates passes bill on prescription drug price gouging by vote of 137 to 4
- Leaked document: March 15, 2017 Note by Switzerland on India EFTA TEPA IP Chapter
- Patients, Members of Congress Ask Chilean Government to Issue Compulsory Licenses on Prostate Cancer and HCV Drug Patents
- Leaked: Three documents from RCEP negotiations
- 14 March 2017 - Senate Finance Committee grills Robert Lighthizer (USTR nominee) on trade and IPR policies
- KEI Testifies in Maryland on Drug R&D Cost Transparency Bill (HB666/SB437)
- HHS Office of Inspector General Declines to Investigate Failure to Disclose Federal Funding in Ionis Pharmaceuticals' Spinraza
- KEI 10 March 2017 Comments on Army Exclusive License on Zika Virus Vaccine Patents to Sanofi
This is an essay about strategic ignorance, as regards evidence relevant to policies that cost consumers and taxpayers billions of dollars.
The United States government grants 20 year patents on pharmaceutical drugs, and it also provides a growing number of other non-patent incentives and subsidies to stimulate R&D investments in new medicines. Are these incentives and subsidies necessary or cost effective? How would anyone know?
Here are some of the incentives we offer:
- Up to five year extensions of patents on pharmaceutical drugs.
February 22 noon Washington, DC meeting to discuss international negotiations on copyright (With international call-in)Submitted by KEI Staff on 14. February 2012 - 14:12
On Wednesday February 22, 2012, from 12:30pm to 2:30pm, KEI will host a roundtable discussion on international copyright negotiations. The location of the meeting will be 1621 Connecticut Ave, NW, Suite 500, Washington, DC 20009. There will be an opportunity to participate by telephone, via toll free calls in many countries. (To register or for details on call-in, email firstname.lastname@example.org. If you want to try to join by skype, we will do our best.)
The topics to be discussed are the following International copyright negotiations:
KEI files affidavit in India compulsory licensing case involving Bayer patents on cancer drug Sorafenib (Nexavar)Submitted by KEI Staff on 14. February 2012 - 10:05
KEI has provided an affidavit in an India compulsory licensing dispute involving Natco and Bayer, for patents on the cancer drug sorafenib (sold by Bayer under the brand name Nexavar).
The Bayer price for sorafenib/Nexavar in India is $47 per 200 milligram tablet. At a daily dose of 4 tablets, this comes to $5,637 per month, or more than $68 thousand per year. In 2010, per capita income in India was $1,330.
Sangeeta Shashikant from TWN recently collected and published several NGO statements on the Africa IP Summit, in the TWO Info Service on Intellectual Property Issues (Feb12/03), which included a link also to a letter to WIPO signed by more than 100 NGOs.
U.S. Dept of Commerce asked to review Africa Intellectual Property Forum compliance w/ Executive Order 13155Submitted by James Love on 10. February 2012 - 12:53
Health GAP, KEI, Oxfam, Public Citizen, Universities Allied for Essential Medicines and Professor Susan Sell have written Cameron Forbes Kerry, the General Counsel for the U.S. Department of Commerce, asking Kerry to "review work on the Africa Intellectual Property Forum, currently scheduled for April 3-5, 2012 in Cape Town, South Africa, to see if the sponsorship of the event violates Executive Order 13155, on Access to HIV/AIDS Pharmaceuticals and Medical Technologies." Executive Order 13155 was issued by President Clinton on May 10, 2000 after an extensive review of U.S.
On February 8, 2012, seven public health organisations submitted a letter to Rep. Darrell Issa (R-CA), Chairman of the Committee on Oversight and Government Reform and the other thirty-nine members of this committee opposing H.R. 3699, the "Research Works Act." This bill, originally introduced on December 16, 2011 by Rep. Issa and Rep. Maloney (D-NY) would prohibit federal agencies from conditioning its federal grants on recipients making its published research results available to the public.
US, France, Japan, South Africa, WIPO, ICC-BASCAP, Lilly, Microsoft and Pfizer co-sponsor Africa IP Forum in Cape TownSubmitted by thiru on 1. February 2012 - 9:40
The United States Department of Commerce's Commercial Law Development Program (CLDP) is the lead agency of a concerted effort involving the governments of France, Japan, South Africa and the United States, alongside the World Intellectual Property Organization (WIPO), Organisation Africaine de la Propriété Intellectuelle (OAPI), and the African Regional Intellectual Property Organization (ARIPO) to organize the inaugural "Africa Intellectual Property Forum: Intellectual Property, Regional Integration and Economic Gr
On January 26, 2012, KEI sent a letter to Senator Patrick Leahy (D-VT), Chairman of the Judiciary Committee, calling for greater transparency in the Trans-Pacific Partnership Agreement (TPPA). The letter highlights the fact that the general public is kept in the dark regarding negotiating positions and the actual text while "cleared advisers" and corporate lobbyists have unequal access to information. It calls for Senator Leahy to urge the Obama Administration to release the negotiating text in order to allow full and effective public participation in our democratic society.
EB130: CMC Churches' Action for Health intervention on the Consultative Expert Working Group on Research and Development (CEWG)Submitted by thiru on 21. January 2012 - 9:08
This was the statement delivered by CMC Churches' Action for Health intervention on 21 January 2012 on the Consultative Expert Working Group on Research and Development: Financing and Coordination at the 130th WHO Executive Board meeting.
CMC Churches' Action for Health intervention on the Consultative Expert Working Group on Research
and Development: Financing and Coordination at the 130th WHO Executive Board meeting
WHO 130th Executive Board Agenda Item 6.14
Intervention by James Love, CMC Churches' Action for Health
Since May 2009, the ACLU and Public Patent Foundation (PUBPAT) have been litigating a case involving the patent eligibility of two human genes, BRCA1 and BRCA2, associated with ovarian and breast cancer. ACLU and PUBPAT, representing the petitioners, Association for Molecular Pathology, among others, have argued that human genes are not patentable and that patents on such objects stifle diagnostic testing and further research.
For call-in details for today's event, contact Krista Cox.
On January 27, 2012, KEI will host a brown bag lunch with Shira Perlmutter. Shira was recently appointed the Administrator for Policy and External Affairs of USPTO. This position was most recently held by Albert Tramposch, who replaced Arti Rai, the first Obama appointee.
WHO reform efforts to consider new modalities for engagement with NGOs, foundations, partnerships and for-profit-organizationsSubmitted by thiru on 11. January 2012 - 5:02
WHO reform is among the hot topics for consideration at the 130th session of the WHO Executive Board which meets from 16 January 2012 to 23 January 2012. One paper in particular, EB130/5 Add.4, entitled, "Governance: Promoting engagement with other stakeholders and involvement with and oversight of partnerships" describes how WHO may re-assess its relationship with non-governmental organizations including,
Response to Federal Register notice seeking comments regarding Canada's interest in TPPA negotiationsSubmitted by Krista Cox on 10. January 2012 - 17:18
On December 7, 2011, USTR issued Federal Register Notice 76480-76481 requesting comments on "Canada's Expression of Interest in the Proposed Trans-Pacific Partnership Trade Agreement." USTR issued similar requests for comments regarding Japan's (Notice 76478-76479) and Mexico's (Notice 76479-76480) expression of interest in the TPPA.
KEI has submitted a response to this notice available for download here.